LO2A studied for Sjögren-related dry eye symptoms

A phase 4 study set in Israel of a potential treatment for dry eye symptoms related to Sjögren’s syndrome has concluded, Wize Pharma announced in a press release.
LO2A, which is marketed in Israel for dry eye syndrome, was tested against Alcon’s Systane Ultra UD (propylene glycol) over-the-counter product in a randomized, double-masked study evaluating about 60 patients with Sjögren’s syndrome and related dry eye symptoms.
Patients were split into two groups and monitored over a 3-month period. Primary endpoint was change in corneal and conjunctival staining score.

Full Story →